Risk of Readmission and Mortality Following Hospitalization with Hypercapnic Respiratory Failure.


Journal

Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875

Informations de publication

Date de publication:
02 2020
Historique:
received: 22 08 2019
accepted: 02 12 2019
pubmed: 13 12 2019
medline: 1 6 2021
entrez: 13 12 2019
Statut: ppublish

Résumé

Hypercapnic respiratory failure (HRF) is a frequent cause of hospitalization and a common comorbidity in hospitalized patients. There are few studies addressing what factors might predict poor outcomes in this patient population. The purpose of the current study was to investigate characteristics and outcomes of patients hospitalized with HRF. A study of patients ≥ 18 years admitted with HRF in a 1-year period. Patients with limited life expectancy related to other conditions, and those with a non-respiratory cause of HRF, were excluded. 202 subjects met eligibility criteria: 24% had a diagnosis of obstructive sleep apnea, 6% obesity hypoventilation, 46% chronic obstructive pulmonary disease, and 10% asthma. Fifteen (7%) died during the index admission. Forty-one patients (23%) were readmitted within 30 days: peripheral vascular disease [adjusted odds ratio (aOR) 4.78, CI 1.45-15.74] and tachycardia (aOR 2.97, CI 1.22-7.26) were associated with an increased risk of readmission. Sixty-six patients (36%) died after discharge. Risk of death was increased in older patients (aOR 1.32, CI 1.13-1.54 per 5 years), those with peripheral vascular disease (aOR 12.56, CI 2.35-67.21), higher Charlson co-morbidity index (aOR 1.39, CI 1.09-1.76), use of home oxygen (aOR 4.03, CI 1.89-8.57), and those who had been readmitted (aOR 3.07, CI 1.46-6.43). Hospitalization for HRF is associated with a high morbidity and mortality. Our observation that home oxygen use was associated with increased mortality suggests that oxygen use could be a risk factor for death in patients with HRF.

Identifiants

pubmed: 31828514
doi: 10.1007/s00408-019-00300-w
pii: 10.1007/s00408-019-00300-w
pmc: PMC7223622
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

121-134

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Am J Respir Crit Care Med. 2010 Aug 1;182(3):325-31
pubmed: 20378728
Respir Med. 2017 Sep;130:92-97
pubmed: 29206640
Clin Med (Lond). 2012 Apr;12(2):188
pubmed: 22586805
Am J Respir Crit Care Med. 2007 Apr 1;175(7):661-6
pubmed: 17234901
Chest. 2012 Nov;142(5):1193-1199
pubmed: 22677348
Clin Chest Med. 2018 Jun;39(2):427-436
pubmed: 29779600
Lancet Respir Med. 2014 Sep;2(9):698-705
pubmed: 25066329
Int J Chron Obstruct Pulmon Dis. 2017 Jun 29;12:1891-1902
pubmed: 28721034
BMJ Open. 2017 Jun 15;7(6):e013924
pubmed: 28619767
Thorax. 2004 Dec;59(12):1020-5
pubmed: 15563699
J Interv Card Electrophysiol. 2019 Sep;55(3):243-250
pubmed: 30612212
Qual Manag Health Care. 2016 Oct/Dec;25(4):191-196
pubmed: 27749715
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
PLoS One. 2018 Oct 31;13(10):e0205457
pubmed: 30379868
Geriatr Gerontol Int. 2018 Oct;18(10):1513-1518
pubmed: 30225904
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Am J Respir Crit Care Med. 2017 Jul 15;196(2):124-125
pubmed: 28707975
ESC Heart Fail. 2015 Mar;2(1):12-19
pubmed: 28834643
JAMA. 2018 Apr 10;319(14):1444-1472
pubmed: 29634829
Am J Med. 2018 Nov;131(11):1324-1331.e14
pubmed: 30016636
Crit Care. 2012 Oct 29;16(5):323
pubmed: 23106947
Ann Am Thorac Soc. 2015 Aug;12(8):1219-25
pubmed: 25871443
Am J Respir Crit Care Med. 2017 Jul 15;196(2):200-207
pubmed: 27973930
Sleep Med Rev. 2017 Aug;34:70-81
pubmed: 27568340
PLoS One. 2014 May 12;9(5):e97563
pubmed: 24819141
Wien Klin Wochenschr. 2018 Oct;130(19-20):561-568
pubmed: 30066095
JAMA. 2017 Jun 6;317(21):2177-2186
pubmed: 28528348

Auteurs

Amber J Meservey (AJ)

University of Vermont, Burlington, USA.

Michael C Burton (MC)

University of Vermont, Burlington, USA.

Jeffrey Priest (J)

University of Vermont, Burlington, USA.

Charlotte C Teneback (CC)

University of Vermont, Burlington, USA.

Anne E Dixon (AE)

University of Vermont, Burlington, USA. anne.dixon@uvmhealth.org.
University of Vermont, Given D209, 89 Beaumont Avenue, Burlington, VT, 05405, USA. anne.dixon@uvmhealth.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH